Glenmark, Sun Pharma, Zydus Lifescience Fueling Pharma Market Growth in August
Exciting Growth in Indian Pharma Market
The Nifty Pharma Index has gained around 37% year to date, with Glenmark, Sun Pharma, and Zydus Lifescience driving this upward momentum. Strong earnings from Indian pharmaceutical companies in the US markets have bolstered this growth trend.
Year-on-Year Performance
- JB Chemicals & Pharmaceuticals: 13.7% growth
- Glenmark Pharma: 13.5% growth
- Intas Pharmaceuticals: 11.4% growth
- Sun Pharmaceutical Industries: 9.9% growth
- Zydus Lifescience: 9.7% growth
- Abbott: 9.5% growth
- Ajanta Pharma: 9.4% growth
As of August 2024, Indian pharma companies hold a majority share of 84% in the Indian Pharma Market.
Future Outlook
Analysts remain positive, with a projected growth rate of 7-9% this fiscal driven primarily by price adjustments and volume boosts from new product launches. The chronic segment is expected to be a major revenue driver as lifestyle diseases rise and health awareness escalates post-pandemic.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.